Trial Profile
A phase IIIb randomized, double-blind study comparing maintenance zd1839 [gefitinib] (Iressa) or placebo following completion of front line, platinum-based, double chemotherapy in subjects with advanced or metastatic non-small cell lung cancer
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms Herbst
- Sponsors AstraZeneca
- 19 Apr 2008 New trial record.